Related Experiment Video

Updated: Jul 17, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy

Dianne S Hirsch1, Wen Jin Wu

  • 1Food and Drug Administration, HFD 123, Bethesda, MD 20892, USA. dianne.hirsch@fda.hhs.gov

Expert Review of Anticancer Therapy
|February 10, 2007
PubMed

Insights

Epidermal Growth Factor Receptor (ErbB1) overexpression in breast cancer may stem from impaired Cbl-mediated degradation, potentially involving Cdc42. This impacts targeted therapy strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • ErbB1 and ErbB2 receptors are frequently overexpressed in breast cancer, correlating with poor prognosis.
  • Targeted therapies for ErbB receptors exist, but ErbB1 overexpression mechanisms are not fully understood.
  • Cbl-mediated ubiquitination and degradation are key for ErbB1 downregulation.

Purpose of the Study:

  • To investigate the mechanisms of ErbB1 overexpression in breast cancer.
  • To explore the role of Cdc42 in regulating ErbB1 levels and Cbl function.
  • To review therapeutic strategies targeting ErbB receptors and Cdc42.

Main Methods:

  • Analysis of ErbB1 and ErbB2 expression in breast cancer tissues.
  • Investigation of Cbl-mediated ErbB1 degradation pathways.
  • Assessment of Cdc42 expression and its correlation with ErbB1 and Cbl.
  • Review of existing and potential therapeutic interventions.

Main Results:

  • ErbB1 overexpression in cancer cells may be linked to the loss of Cbl-regulated degradation.
  • Activated Cdc42 is implicated in ErbB1 accumulation by affecting c-Cbl function.
  • Gene amplification is a common cause of ErbB2 overexpression, unlike ErbB1.

Conclusions:

  • Dysregulation of Cbl-mediated ErbB1 degradation and the role of Cdc42 are critical factors in ErbB1 overexpression.
  • Understanding these mechanisms is essential for developing effective targeted therapies for breast cancer.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...